Hepatitis C virus and Human Immunodeficiency Virus coinfection among attendants of Voluntary Counseling and Testing Centre and HIV follow up clinics in Mekelle Hospital

Haftom Hadush1,2, Solomon Gebre-Selassie2, Adane Mihret2,3,*

1Department of Microbiology, Immunology and Parasitology, School of Medicine, Wollega University, P.O.Box 395, Nekemte, Ethiopia, 2Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, Ethiopia, 3Armauer Hansen Research Institute, P.O.Box 1005, Addis Ababa, Ethiopia

*Corresponding author: Adane Mihret, Department of Microbiology, Immunology and Parasitology, School of Medicine, Addis Ababa University, Armauer Hansen Research Institute, P.O.Box 1005, Addis Ababa, Ethiopia

Key words: Hepatitis C virus, human immunodeficiency virus, co-infection, seroprevalence

Received: 19/12/2012 - Accepted: 08/03/2013 - Published: 18/03/2013

Abstract

Introduction: Hepatitis C virus remains a large health care burden to the world. HIV and HCV co-infection is major global health concern worldwide. However, there is limited information on the prevalence of HCV/HIV co-infection in Ethiopia. The aim of the study was to assess the magnitude of HIV/HCV co-infection and the potential risk factors in attendants of voluntary counseling and testing centre and HIV follow up clinics of Mekelle hospital. Methods: A cross sectional seroprevalence survey of HCV infection was carried out on 300 HIV negative and positive subjects attending voluntary counseling and testing (VCT) center and HIV follow up clinics of Mekelle hospital, Ethiopia from December 2010-February 2011. Serum samples were tested for anti-HCV antibodies using immunochromatographic test. Results: Of the 300 study participants, 126(42%) were HIV negative and 174(58%) HIV seropositive from VCT and HIV follow up clinics, respectively. The overall anti-HCV prevalence was 18(6.0%). There were no significant differences in HCV seroprevalence among the different categories of age and sex (p> 0.05). Of the 174 persons with HIV, 16 (9.2%) cases had antibodies to HCV, where as among 126 HIV negative subjects 2 (1.58%) were HCV seropositive (p=0.006, OR= 6.28, 95% CI= 1.42-27.82). Conclusion: Accordingly, there was a significant difference in sero-positivity of HCV between HIV positive and HIV negative participants. No apparent risk factor that caused HCV infection was inferred from this study.

Pan African Medical Journal. 2013; 14: 107. doi:10.11604/pamj.2013.14.107.2302

This article is available online at: http://www.panafrican-med-journal.com/content/article/14/107/full/

© Haftom Hadush et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Hepatitis C virus (HCV) is a significant healthcare problem affecting more than 170 million people worldwide and as many as four million new infections occur annually [1] HCV may increase the rate of progression to acquired immune-deficiency syndrome (AIDS), impair immune reconstitution and the risk of hepato-toxicity. HCV infection increases the number of complications in persons who are co-infected with human immune-deficiency virus (HIV) [2]. Of those exposed to HCV, 80% become chronically infected, and at least 30% of the carriers develop chronic liver disease [3]. Risk factors associated with HCV infection include injection drug use, receipt of blood products, long term haemo-dialysis, organ transplantation, receipt of tattoo from unsanitary facilities, vertical transmission during pregnancy and sexual exposure [4]. The WHO estimated that about 3% of the world’s population is chronically infected with HCV [5]. The overall prevalence in Sub-Saharan Africa is estimated 3% [6]. Decline of mortality due to opportunistic infections in HIV-infected patients since the introduction of highly active antiretroviral therapy (HAART) has led to an increase in morbidity and mortality related to hepatitis virus infections. Co-infection of HIV and HCV is common because of their similar routes of transmissions of exposure. The sero-prevalence of HCV in Ethiopia was reported as 7.5% [7] and HIV/HCV co-infection rate was 1.4%-11.6% [8-10]. Screening of blood products is the only way to prevent transfusion associated cases. Diagnostic tests for HCV infection include serologic tests to detect HCV antibodies, molecular tests and genotyping techniques [11]. Screening based on antibody detection has markedly reduced the risk of transfusion-related infection [12]. The aim of the study was to assess the magnitude of HIV/HCV co-infection rate and potential risk factors are associated with HCV sero-positivity among consecutive attendants of voluntary counseling and testing (VCT) centre and HIV follow up clinics of Mekelle hospital.

**Methods**

Study population, data collection and laboratory procedures. The prospective study was conducted during December 2010 to February 2011 among attendants of VCT centre and ART clinic in Mekelle hospital, North Ethiopia. Three hundred subjects (126 HIV-negative from VCT and 174 HIV-positive subjects in ART follow up) were enrolled in the study. Socio-demographic data including risk behaviors, drug injection, dental procedure, catheterization, surgery, blood transfusion, hospitalization, history of tattooing, scarification and bloodletting were collected. Five millilitre of blood sample was collected by finger prick from consecutive attendants of VCT and ART clinics in the hospital. Serum was screened for anti-HCV antibody using rapid test kits (Flavivick-HCV WB, Qualpro diagnostics, India) and one step HCV serum test strip (Biocare TM diagnostics, China). The reactive sera were further tested by Enzyme-Linked Immuno-sorbent assay (ELISA) for confirmation. HIV and anti-HCV positive samples were retested by 4th generation ELISA assay (HCV antibody ELISA, Human diagnostics, Germany). The presence of antibodies to HIV was determined using different immune-chromatography rapid test kits: HIV 1+2 Rapid Test Strip (Shanghai Kehua Bioengineering co., Ltd), HIV ½ STAT-PAK Assay (Chembio Diagnostic Systems, Inc.) and Uni-Gold HIV (Trinity biotech plc, Ireland). Drops of blood were taken by finger-prick using pipette. About 40?l of the sample was added to the HIV 1+2 rapid test cassette and then one drop of the sample diluent was added to the same area. After 2-3 min, one band if negative or two bands if positive were observed. When the anti-HIV was positive by the HIV Rapid Test from, the sample was retested by the second HIV ½ STAT-PAK assay. HIV-seropositive subjects were counseled and negative sera were retested by the second Rapid Test and confirmed by Uni-Gold HIV test. Rapid test reactive specimens were retested using 4th generation ELISA assay.

**Data analysis**

Data were analyzed using SPSS 17.0 statistical software. Chi-square ($\chi^2$) test was utilized to compare variables. P-value <0.05 was considered as significant. Odds ratio (OR) and 95% confidence interval (CI) were used to measure the strength of association.

**Ethical considerations**

Ethical clearance was obtained from Department of Microbiology, School of Medicine of Addis Ababa University. Informed written consent was obtained from study participants.

**Results**

Of the 300 participants, 181(60.3%) were females (male to female ratio was 0.6:1). The mean age of the participants was 28.95±9.4 (range: 6 months to 63 years). The majority, (53.0%) were adults aged 20-29 year of age. Children 60 years age were 1.3% (Table 1).

Of the 300 study participants tested for anti-HCV, 135(74 females, 61 males) were from VCT centre and 165(107 females, 58 males) were HIV positive cases from ART clinic in Mekelle hospital. Among the 174 HIV positive subjects, 16(9.2%) were positive for HCV antibody. The prevalence of HCV infection among HIV negative VCT centre attendants was 2/126(1.6%). The overall prevalence of anti-HCV antibody was 18(6.0%) (95%CI, 3.6-9.3). The age specific prevalence was higher 1/8(12.5%) for the 50-59 year age groups. Males positive for anti-HCV were 5(4.2%) while females were 13(7.2%). HCV infection was higher in females than males (OR, 0.57; 95%CI, 0.20-1.63, P=0.33) (Table 1).

The overall prevalence of HIV/HCV co-infection in HIV positive patients was 16(9.2%). Of the 174 persons with HIV, 5/62(8.1%) were males and 11/112(9.8%) females. Among 126 HIV-negative subjects, 2(1.6%) females were positive for HIV-antibody. The proportion of HCV infection in HIV cases was increased nearly 6 fold compared to HIV negative individuals which was 9.2% and 1.6%, respectively (OR, 6.28; 95%CI, 1.42-27.82, P=0.006) (Table 2). The age specific pattern of HIV and HCV co-infection shows that the frequency of HCV infection was in similar trend to the frequency of HIV infection in each age group of the study subjects. A relatively higher proportion of HCV infection was observed in respondents with history of multiple sex partners and using tattoo, 6/59(10.2%) and 3/35(8.6%), respectively. A total of 2(8.3%) respondents had history of admission to hospital, 1/17(5.9%) had history of dental procedure (Table 3). Regarding the various occupational groups, 2(11.1%) of 18 farmers had positive HCV-antibody and 5/50(10.0%) of office workers had HCV prevalence, while daily laborers had 4/43(9.3%) prevalence (Table 4).

**Discussion**

Sero-prevalence of HCV among HIV positive individuals of 16(9.2%) is higher than HIV-negative of 2(1.6%). This result is higher than the 0.7% report in HIV-positive subjects by Tessema et al [13] and 1.7% by Gelaw and Mengistu [14]. Lower HIV/HCV co-infected rates
were reported from Gambia [15], Nigeria [16], South Africa [17] and Uganda [18], in 0.6%, 1.86%, 1.9% and 3.3%, respectively. In India, prevalence of HCV-antibody in HIV-positive patients showed 1.6% [19]. In Nigeria, another study showed 2.3% HCV-antibody co-infection in HIV-positive patients [20] while in Greece 7.5% [21]. In a similar study carried out in Iran, the co-infection rate of HCV in HIV-positive patients was 74% [22]. Findings of 8.2% in Nigeria [23] and 8.6% in Cameroon [24] were reported which were comparable with the present study. In contrast, the co-infection rate obtained in the present study 9.2% is lower than 11.6% reported by an earlier study in VCT and HIV follow up clinic [8]. This was lower than co-infection rate of 30-50% reported some industrialized countries, such as in North America and Europe [25,26], where intravenous drug use (IDU) is a major risk factor for both infections. The high co-infection rate in HIV-positive persons could demonstrate that patients may be exposed to HCV infection by sexual contact and it suggests co-transmission of both viruses [9]. The frequency of HCV transmission to sexual partners is significantly higher when HIV virus is also transmitted. This would suggest that HIV could be co-factor for the sexual transmission of HCV infection [27]. Therefore, investigation of HCV in HIV-positive patients is vital in order to take care of them [28]. This finding agrees with other studies in where HCV infection was significantly higher in HIV infected cases than in HIV negative individuals 11.6% vs 2.6% [8]. In addition, Tessema et al [13] reported the presence of a significant association between HCV and HIV infections. The possible elucidation for this variation might be due to the rapid test positive samples in the present study was not confirmed by other tests.

The overall prevalence of HCV infection among HIV negative persons was 2/126(165%). This result is lower than the 5% rate observed among VCT attendants reported by Gebre [8]. Injection drug use is uncommon in the study area. Regarding occupational groups, 2/8(11.1%) of farmers were positive for HCV-antibody and office workers had HCV prevalence of 5/50(10.0%), while day laborers had 4/43(9.3%) prevalence. In another study, HCV-antibody distribution with respect to occupation was reported uniform [8]. Seroprevalence rates of HCV antibody was higher in individuals with multiple sex partners and in sex workers suggesting that sexual transmission may be possible.

This study has several limitations. Supplemental anti-HCV testing (i.e., RIBA) for all anti-HCV positive confirms the presence of anti-HCV. The presence of screening test negative result is common in immune-suppressed individuals (HIV infection) and during window period of the disease. Hence, these assays do not exclude the possibility of exposure to HCV virus for the individuals with negative results.

**Conclusion**

Co-infection rate of HIV/HCV in this study is high. Thus, diagnosing HCV in HIV-positive patients is vital in order to take care of them and allot resources in health planning. Preventive measures against HCV should target primarily on HIV infected people. Therefore, providing opportunity of screening for HCV infection in all HIV-infected patients is essential. Implementation of more effective public health education and counseling are essential to reduce the dangers of HIV/HCV co-infection.

**Competing interests**

The authors declare no conflict of interests.

**Authors’ contributions**

HH conceived the study. HH, SG and AM initiated and designed the study. HH conducted the laboratory work, undertook statistical analysis and drafted the manuscript. SG and AM corrected the manuscript. All authors contributed to the writing of the manuscript and approved the submitted version of the manuscript.

**Acknowledgments**

We extend our gratitude to Addis Ababa University, School of graduate studies, Tigray Regional Health Bureau and staff members of Mekelle hospital for their assistance.

**Tables**

**Table 1**: HCV prevalence by age and sex in attendants of VCT centre and HIV follow up clinics, Mekelle hospital

**Table 2**: Coinfection of HIV and HCV in attendants of VCT centre and HIV follow up clinics, Mekelle hospital.

**Table 3**: HCV prevalence by risk factors in attendants of VCT centre and HIV follow up clinics, Mekelle hospital.

**Table 4**: HCV prevalence by occupation in attendants of VCT centre and HIV follow up clinics, Mekelle hospital.

**References**

1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006; 3:47-52. PubMed | Google Scholar

2. Thomas DL, Leoutsakas D, Zabransky T, et al. Hepatitis C in HIV-infected individuals: cure and control, right now. Int AIDS Soc. 2011; 14: 22. PubMed | Google Scholar

3. Sultan MT, Rahman MM, Begum S. Epidemiology of hepatitis C virus (HCV) infection. J Bangladesh Coll Phy Surg. 2009; 27: 160-162. PubMed | Google Scholar

4. Murray KF, Richardson LP, Morishima C, et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics. 2003; 111: 153 - 157. PubMed | Google Scholar

5. WHO. Global surveillance and control of hepatitis C: Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999; 6:35-47. PubMed | Google Scholar

6. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis. 2002; 2:293-302. PubMed | Google Scholar

7. Diro E, Alemu S, Gebre-Yohannes A. Blood safety and prevalence of transfusion transmissible viral infections among donors at the Red Cross Blood Bank in Gondar University
8. Gebre K. Hepatitis C virus and HIV coinfection among attendants of voluntary counseling and testing center, and HIV follow up clinics at Tikur Anbessa Hospital. Addis Ababa, Ethiopia. Faculty of Medicine, AAU. 2005. PubMed | Google Scholar

9. Ayele W, Nokes DJ, Abebe A, et al. Higher prevalence of anti-HCV antibodies among HIV positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol. 2002; 68: 12-17. PubMed | Google Scholar

10. Feld JI, Ocam P, Ronald A. The liver in HIV in Africa. Antivir Ther. 2005; 10: 953-965. PubMed | Google Scholar

11. Richter SS. Laboratory Assays for Diagnosis and Management of Hepatitis C Virus Infection. J Clin Microbiol. 2002; 40: 4407-4412. PubMed | Google Scholar

12. Lauer, GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001; 345:41-52. PubMed | Google Scholar

13. Tessema B, Yismaw G, Kassu A, et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia. BMC Infect Dis. 2010; 10: 111-17. PubMed | Google Scholar

14. Gelaw B, Mengistu Y. The prevalence of HIV, HCV and malaria parasites among blood donors in Amhara and Tigray Regional States, Ethiop J Health Dev. 2008; 22: 3-7. PubMed | Google Scholar

15. Mboto CI, Fielder M, Russell A, Jewell AP. Prevalence of HIV-1, HIV-2, Hepatitis C and Co-Infection in the Gambia. West Afr J Med. 2009; 28: 306-309. PubMed | Google Scholar

16. Onakworo JUE, Okonofua FE. The Prevalence of dual human immunodeficiency virus/ hepatitis C virus (HIV/HCV) infection in asymptomatic pregnant women in Benin City, Nigeria. Afr J Reprod Health. 2009; 13: 97-108. PubMed | Google Scholar

17. Amin J, Kaye M, Skidmore S, et al. HIV and hepatitis C coinfection within the CAESAR study. HIV Med. 2004; 5:174-9. PubMed | Google Scholar

18. Walusansa V, Kagimu M. Screening for hepatitis C among HIV positive patients at Mulago Hospital in Uganda. J Afr Health Sci. 2009; 9: 143-146. PubMed | Google Scholar

19. Tripathi AK, Khanna M, Gupta N, et al. Low Prevalence of HBV and HCV co-infection in Patients with HIV in Northern India. J Assoc Physicians India. 2007; 55: 429-31. PubMed | Google Scholar

20. Adewole OO, Anteyi E, Ajuwon Z, et al. Hepatitis B and C coinfection in Nigerian patients with HIV. J Infect Dev Countries. 2009; 3: 369-375. PubMed | Google Scholar

21. Dimitrakopoulos A, Takou A, Haida A, et al. The prevalence of hepatitis B and C in HIV?positive Greek patients: relationship to survival of deceased AIDS patients. J Infect. 2000; 40: 127-131. PubMed | Google Scholar

22. Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 coinfection among injection drug user patients hospitalized at the infectious disease ward of training hospital in Iran. Pak J Med Sci. 2007; 23: 510-13. PubMed | Google Scholar

23. Agwale SM, Tanimoto L, Womack C, et al. Prevalence of HCV coinfection in HIV infected individuals in Nigeria and characterization of HCV genotypes. J Clin Virol. 2004; 31: S3-6. PubMed | Google Scholar

24. Kim S, Hu J, Gautum R, et al. HIV and Hepatitis C virus coinfection, Cameroon. Emerg Infect Dis. 2007; 13: 248-260. PubMed | Google Scholar

25. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44: S6-9. PubMed | Google Scholar

26. Verucchi G, Calza L, Manfredi R, et al. HIV and HCV coinfection epidemiology, natural history, therapeutic options, and clinical management. Infection. 2004; 32: 33-46. PubMed | Google Scholar

27. Pembye L, Newell ML, Tovo PA. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of HCV. Brit J Obstet Gynaecol. 2001; 108: 371-377. PubMed | Google Scholar

28. Bruno R, Sacchi P, Puoti M, et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr. 2007; 46: 297-303. PubMed | Google Scholar

---

**Table 1**: HCV prevalence by age and sex in attendants of VCT centre and HIV follow up clinics, Mekelle hospital

| Age group (years) | HCV-Antibody positive No (%) | Total No (%) |
|------------------|-----------------------------|--------------|
|                  | Males | Females |                   |
| 0-9              | 0(0.0)| 0(0.0)  | 0(0.0)            |
| 10-19            | 0(0.0)| 1(25.0)| 1(9.1)            |
| 20-29            | 2(3.9)| 7(6.5)  | 9(5.7)            |
| 30-39            | 2(6.5)| 3(5.5)  | 5(5.8)            |
| 40-49            | 0(0.0)| 2(25.0)| 2(8.7)            |
| 50-59            | 1(14.3)| 0(0.0) | 1(12.5)           |
| >60              | 0(0.0)| -       | 0(0.0)            |
| **Total**        | 5(4.2)| 13(7.2)| **18(6.0)**       |
### Table 2: Coinfection of HIV and HCV in attendees of VCT centre and HIV follow up clinics, Mekelle hospital

| HIV status | HCV antibody | Total No (%) | OR, 95% CI | P value |
|------------|--------------|--------------|------------|---------|
|            | Positive No (%) | Negative No (%) |            |         |
| Positive   | 16(9.2)       | 158(90.8)    | 174        | 6.28(1.42-27.82) | 0.006 |
| Negative   | 2(1.6)        | 124(98.4)    | 126        | -        | -     |
| Total      | 18(6.0)       | 282(94.0)    | 300(100)   | -        | -     |

### Table 3: HCV prevalence by risk factors in attendees of VCT centre and HIV follow up clinics, Mekelle hospital

| Risk factors       | HCV-antibody, No (%) | OR (95% CI) | p value |
|--------------------|----------------------|-------------|---------|
|                    | Positive | Negative | Total |
| Community acquired |          |          |        |
| Tattooing          | 3(8.6)   | 32(91.4) | 35(14.0) | 1.56(0.43-5.69) | 0.45 |
| Blood letting      | 0(0.0)   | 8(100.0) | 8(3.2)  | -        | 1.00 |
| Scarification      | 1(3.1)   | 31(96.9) | 32(12.8) | 0.48(0.06-3.70) | 0.70 |
| Hospital acquired  |          |          |        |
| Hospitalization    | 2(8.3)   | 22(91.7) | 24(9.6)  | 1.48(0.32-6.84) | 0.65 |
| Blood transfusion  | 0(0.0)   | 6(100.0) | 6(2.4)   | -        | 1.00 |
| Dental procedure   | 1(5.9)   | 16(94.1) | 17(6.8)  | 0.98(1.22-7.82) | 1.00 |
| Minor surgery      | 0(0.0)   | 16(100.0) | 16(6.4)  | -        | 0.61 |
| Behavioral acquired|          |          |        |
| Multiple sex partners | 6(10.2) | 53(89.8) | 59(23.6) | 2.16(0.78-6.02) | 0.14 |
| STI/STD            | 0(0.0)   | 30(100.0) | 30(12.0) | -        | 0.23 |
| Abortion           | 0(0.0)   | 23(100.0) | 23(9.2)  | -        | 0.38 |
| Total              | 13(5.2)  | 237(94.8) | 250(100.0)| -        | -     |

### Table 4: HCV prevalence by occupation in attendees of VCT centre and HIV follow up clinics, Mekelle hospital

| Occupational category | HCV-antibody (%) | Total |
|-----------------------|------------------|-------|
|                       | Positive | Negative |
| Health workers        | 0(0.0)   | 2(100.0)  | 2(0.7) |
| Sex workers           | 1(6.7)   | 14(93.3)  | 15(5.3) |
| Day laborers          | 4(9.3)   | 39(90.7)  | 43(15.4) |
| Office workers        | 5(10.0)  | 45(90.0)  | 50(17.9) |
| Handicrafts           | 0(0.0)   | 12(100.0) | 12(4.3) |
| Farmers               | 2(11.1)  | 16(88.9)  | 18(6.4) |
| Merchants             | 0(0.0)   | 1(100.0)  | 1(0.4)  |
| Housewives            | 3(3.6)   | 80(96.4)  | 83(29.6) |
| Drivers               | 0(0.0)   | 7(100.0)  | 7(2.5)  |
| No job                | 2(4.1)   | 47(95.9)  | 49(17.5) |
| Total                 | 17(6.1)  | 263(93.9) | 280(100.0) |